Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)
The treatment landscape of metastatic non-small cell lung cancer (NSCLC) has dramatically
evolved in recent years, since the recognition of several clinical–biological entities requiring …
evolved in recent years, since the recognition of several clinical–biological entities requiring …
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 …
M Wislez, C Domblides, L Greillier, J Mazières… - Lung Cancer, 2021 - Elsevier
Introduction HIV is an exclusion criterion for most lung cancer (LC) trials, however LC is the
most common non-AIDS-defined malignancy in people living with HIV (PLHIV), poorer …
most common non-AIDS-defined malignancy in people living with HIV (PLHIV), poorer …
Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort
K Noonan, KM Tong, J Laskin, B Melosky, S Sun… - Lung Cancer, 2014 - Elsevier
Introduction Chemotherapy improves overall survival (OS) in advanced non-small cell lung
cancer (NSCLC), yet low rates of chemotherapy utilization have been observed. We sought …
cancer (NSCLC), yet low rates of chemotherapy utilization have been observed. We sought …
[HTML][HTML] First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of …
M Mark, P Froesch, K Gysel, SI Rothschild… - European Journal of …, 2024 - Elsevier
Introduction The safety and efficacy of first-line durvalumab in PS2 patients with advanced
NSCLC is unknown. Here, we present the primary analysis of first-line durvalumab in PS2 …
NSCLC is unknown. Here, we present the primary analysis of first-line durvalumab in PS2 …
[HTML][HTML] Злокачественное новообразование бронхов и легкого
КК Лактионов, ЕВ Артамонова… - Современная …, 2022 - cyberleninka.ru
ЗЛОКАЧЕСТВЕННОЕ НОВООБРАЗОВАНИЕ БРОНХОВ И ЛЕГКОГО – тема научной статьи
по клинической медицине читайте бесплатно текст научно-исследовательской работы в …
по клинической медицине читайте бесплатно текст научно-исследовательской работы в …
Analysis of advanced lung cancer patients diagnosed following emergency admission
D Fujimoto, R Shimizu, T Morimoto… - European …, 2015 - Eur Respiratory Soc
Data on prognosis and predictors of overall survival in advanced lung cancer patients
diagnosed following emergency admission (DFEA) are currently lacking. We retrospectively …
diagnosed following emergency admission (DFEA) are currently lacking. We retrospectively …
[HTML][HTML] A phase 1, open-label, dose-escalation study of L-DOS47 in combination with pemetrexed plus carboplatin in patients with stage IV recurrent or metastatic …
S Piha-Paul, G Simon, CP Belani, H Chao… - JTO Clinical and …, 2022 - Elsevier
Introduction L-DOS47, a targeted urease–anti-CEACAM6 immunoconjugate, alters the
acidity of the tumor microenvironment by increasing local ammonia production. In vitro, the …
acidity of the tumor microenvironment by increasing local ammonia production. In vitro, the …
Engaging patients with late-stage non-small cell lung cancer in shared decision making about treatment
RE Myers, SM Advani, P Myers, P Selvan… - Journal of Personalized …, 2021 - mdpi.com
Few treatment decision support interventions (DSIs) are available to engage patients
diagnosed with late-stage non-small cell lung cancer (NSCLC) in treatment shared decision …
diagnosed with late-stage non-small cell lung cancer (NSCLC) in treatment shared decision …
Platinum combination chemotherapy is poorly tolerated in malnourished advanced lung cancer patients with poor performance status
T Fujio, K Nakashima, T Naito, H Kobayashi… - Nutrition and …, 2019 - Taylor & Francis
This study aimed to explore the tolerability and safety of platinum combination
chemotherapy in malnourished patients with advanced non-small cell lung cancer (NSCLC) …
chemotherapy in malnourished patients with advanced non-small cell lung cancer (NSCLC) …
Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non–small cell lung …
DR Spigel, JD Hainsworth, MJ Joseph, DL Shipley… - Cancer, 2018 - Wiley Online Library
BACKGROUND The best treatment for patients with advanced non–small cell lung cancer
(NSCLC) and a poor performance status is not well defined. In this phase 2 trial, patients …
(NSCLC) and a poor performance status is not well defined. In this phase 2 trial, patients …